thanks Nicole, and to you, joining today. everyone Thank us for
only of the are exciting of pleased Phase us the milestones X quarter commitments. one has we ORCA-VX yet and Phase we for major II adult efficacy XXXX Not in III April, first our most second year, us and delivering These The but continue to received of initiation trial reach to safety Achieve. half NIH, the we been from were proceed for allowing with did trial from of successful announce in also the the results our funding grant on users the to in of e-cigarettes. ORCA-X
likely preventable in you American to and recently, e-cigarettes lost there nicotine and political or have death, and cause the read XXX,XXX attention U.S. smoking surrounding leading of the Tobacco in use debate be arena. more is continues year. than disease resulting great heard lives As each
agreement regulation increase limit lowering solve reverse at increasing nicotine to flavors end And youth the do products many in if taken and available to increased are to menthol take up while trend. health access to hand. be the and potential at not content scrutiny save an nicotine must they restrictions controversial they nicotine are of as that We proceeding be problem restricting such to such the nicotine products, all. addiction action smokers years lives, they may likely implemented will to and of improve over The as addiction
important cytisinicline to nicotine our bringing combustible than FDA solutions already their e-cigarette users as overcome e-cigarette as FDA, considering want more advancing non-nicotine approved good. cigarettes. offering future. we move us believe tailwind why agency have by back need actions cytisinicline FDA seen for products, Smokers nicotine in smoking the for it's would a soon the including cytisinicline through U.S. smokers to on on users With be to heightened as by treatment to we a of regulation the of approved of to reports ever move them hope near to the for and the quit focus market who recent in e-cigarette to first help X addiction. prescription JUUL, the the provides nearly continue That If forward millions we the look And cessation nice possible. market to is decades, mission
with trial. trial events impressive excellent were able the validate more of of sets our adult cytisinicline medical of step to safety X-milligram presenting Xx in received at study additional The likely April, behavioral support results that As cytisinicline smoking smokers and ORCA-X look goal study. this announced one once cytisinicline and durations accomplishing the in who cytisinicline, U.S. adverse results safety cigarette X of placebo. evaluated The the to conferences. submitted was X- we year, to the ORCA-X trial evaluated XXX rates were and we will all who to cytisinicline profile therapy for in observed. for The trial profile first from participants of journal future indicating publication XX-week be data both times duration for with quit single-digit we hand. closer The throughout XX-week X and And Phase to very both smokers positive, smokers standard III in compared X- compared efficacy were overwhelmingly results The received treatment to ORCA-X this and forward of daily received placebo dosed trial in tolerability again are the the to the
are updates provide additional released. will We as data
withdrawal treatment symptoms overall you tolerability key maintain strong and even the their better think ultimately as that point current side outcomes nausea cessation a warnings smokers vomiting, leading products. dreams, offering treatment is cytisinicline making of treatment enough believe as to due of such using which available. utilization be rates discontinuation smokers the prescription of Quitting historically and and feel differentiation a looking have profile worse. of will without should tolerable limits compliance, increases doctors We once smoking difficult high cytisinicline to continue for and help had the effects more therapies quit. black-box product to abnormal We Smoking to insomnia, consider troublesome
the months. first versus of for and is the to year. smokers. be will coming cytisinicline As placebo results of XXX is enrolling we III we in dosing next smoking the The milestone next enroll has cessation will continue to design We this in the which we third smokers endpoints XX the available by to our to look schedule to it line of in across forward confirmatory Phase clinical trial first treatment completion similar half using ahead for same enrollment evaluation. ORCA-X, second be the this that when in XX to U.S. in trial in aims This was X the the and the program, ORCA-X weeks the ORCA-X currently end expect trial quarter we year. smokers anticipate of trial quarter locations continue update And initiated to for top the enrollment next to completed on and look evaluate occur year of anticipate
enroll Professor vapes. has ORCA-VX cytisinicline X efficacy ORCA-X the to Rigotti, aims Harvard treatment School funding compared to our weeks day In Nancy XXX potential trial. Massachusetts times is dosed million Research NIH users approximately for of Director nicotine at the $X.X Medical initiated cytisinicline nicotine Phase Moving June, to or e-cigarette from arms which ORCA-VX for adult e-cigarettes on and us in funding to Hospital. continued this and a evaluating and the thanks at the awarded in led of II the NIDA, XX Center we U.S. our next conduct ORCA-VX trial, grant safety the of X the and and Treatment General of Medicine Tobacco and to PI, X-milligram Dr. placebo. by users
secondary timing nicotine participants treatment weeks will from is the with abstinence all Vaping study ORCA vaping As defined cessation. weeks for trials, of and cessation X weeks as Other in weekly as encouraged There vaping X abstinence this of vaping X assessed to other for the weekly The primary patient to trial. are as in support. as of and last we also for the we outcomes, far seeing great receive recruitment objective will enthusiasm in successful well terms nicotine X will during be evaluate nicotine between example, by the what for is for behavioral ORCA-VX, interest period. be vaping XX. thus XX-week to reduction any are
users enrollment were treatments vapes. of U.S. in and alone the The the first the to of CDC that top FDA-approved XXXX there There nearly for completed nicotine next currently specifically be We fourth half no e-cigarette e-cigarettes users in line are in year. indicated or quarter million expect adult of reported XXXX. XX results in
In conducted And in is health believed next than With Achieve turn has for consequences will it survey interested the them ultimately be would stated trying abstinence to to XX% natural from is for good. XX over nicotine treatment vaping of nicotine of many. believe to goal quit While majority population, present financial potential traditional the X I are noncombustible overwhelming the e-cigarette cigarettes, months. nicotine and intended of cytisinicline this great call to a vape meet to the prescription that now to lower quit forms users, needs for complete help who by an a participants update. approximately of We they that, Jerry our in so. new ready do
